Eleison Pharmaceuticals Announces Initiation of Phase 3 Trial of Glufosfamide for Second-line Treatment of Pancreatic Cancer

Published: Oct 08, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ST. PETERSBURG Fla., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, announced it has initiated a Phase III study of Glufosfamide for the second-line treatment of patients with pancreatic cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news